Abuse-Resistant Oxycodone Approved
Oxecta ingredient discourages extra doses
MONDAY, June 20 (HealthDay News) -- Oxecta, an abuse-resistant form of the top-selling painkiller oxycodone, has been approved by the U.S. Food and Drug Administration.
The immediate-release medication contains niacin, which is designed to cause uncomfortable flushing and skin irritation if a person takes more than the recommended amount. Oxecta is similar to Purdue Pharma's best-selling prescription painkiller Oxycontin, a long-acting opioid drug that's commonly abused.
Oxecta shouldn't be used in people who have severe asthma, upper-airway obstruction or chronic obstructive pulmonary disease (COPD), drug makers Pfizer and Acura Pharmaceuticals said in a news release. Common adverse reactions include nausea, constipation, vomiting, headache, itchiness, insomnia, dizziness and lack of energy, the companies said.
Pfizer is based in New York City, and Acura in Palatine, Ill.
More information
The National Library of Medicine has more about oxycodone.
Scott Roberts Related Articles- Pain a Common Problem for People With COPD
May 21, 2013 - Revised Sunscreen Labels Should Help Consumers Make Wiser Choices
May 20, 2013
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.
Sharp HealthCare is a 2007 Malcolm Baldrige National Quality Award Recipient